Vivos Inc. Submits IDE Application for RadioGel
Kennewick, WA – Vivos Inc. (OTCQB: RDGL) has recently unveiled a major advancement in its commitment to revolutionize cancer care. The company announced the submission of its Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) for RadioGel, an innovative hydrogel-based radioactive therapy aimed at targeting solid tumors.
Understanding the Significance of the IDE Submission
This submission to the FDA is a pivotal moment for Vivos Inc. It carries with it extensive data derived from both animal and human studies, paving the way for what the company hopes will be a significant breakthrough in cancer treatments. With RadioGel, Vivos aims to deliver precise radiation directly to tumors, thus significantly reducing the collateral damage to adjacent healthy tissues, a challenge that has long plagued traditional cancer therapies.
The development of the IDE application was not a solitary endeavor; it resulted from months of collaboration with the FDA under the Breakthrough Device program. This initiative is designed to accelerate the approval process for medical devices that address serious or life-threatening conditions. Through this pathway, the company has sought to alleviate concerns regarding the safety and efficacy of RadioGel, bolstering its submission with a robust compilation of evidence.
Leadership’s Vision for the Future of Cancer Treatment
Dr. Michael Korenko, the CEO of Vivos Inc., expressed his enthusiasm regarding the application, stating, "This is our most comprehensive IDE submission to date, backed by both animal and human data. The constructive discussions we had with the FDA were instrumental in shaping this submission, and they underscore our commitment to delivering transformative therapies to those in need of cancer treatments."
What Sets RadioGel Apart?
RadioGel stands out in the realm of cancer therapies because of its innovative approach to radiation delivery. Traditional therapies often result in collateral damage to healthy tissues; however, RadioGel is designed to minimize this risk, which could lead to a better quality of life for patients undergoing treatment. These qualities make RadioGel a promising solution in the ongoing battle against cancer.
The Next Steps for Vivos Inc.
As Vivos Inc. awaits feedback from the FDA on its IDE application, the company remains focused on advancing its mission to introduce effective new therapies to the market. This is not merely about gaining regulatory approval; it's about changing the landscape of cancer treatment to offer more hope and better outcomes for patients facing tough battles against tumors.
Interested parties can reach out directly to Vivos Inc. through its CEO, Dr. Michael Korenko, via email at MKorenko@RadioGel.com.
Frequently Asked Questions
What is the aim of Vivos Inc.'s IDE application?
Vivos Inc. aims to gain FDA approval for RadioGel, a new cancer treatment that delivers targeted radiation to solid tumors.
What is RadioGel?
RadioGel is a hydrogel-based radioactive therapy designed to minimize damage to surrounding healthy tissue while targeting tumors.
How does this IDE submission impact cancer treatment?
This submission represents a significant advancement by offering a potential new treatment option that uses precision delivery of radiation.
Who is leading Vivos Inc.?
Dr. Michael Korenko serves as the President and CEO of Vivos Inc. and is a driving force behind the company’s innovations.
How can I follow updates from Vivos Inc.?
You can follow Vivos Inc. on X (Twitter) under the handle @VivosIncUSA for the latest insights and updates.
